Trials / Completed
CompletedNCT00947440
Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation
An Open-Label, Randomized, Crossover Study to Evaluate the Bioavailability of Two Candidate Tablet Formulations of ABT-072 With Reference to the Capsule Formulation
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the bioavailability, safety, tolerability and pharmacokinetics of two tablet formulations as compared to the capsule formulation suspended in liquid.
Detailed description
A single-dose, three period, complete cross-over study to evaluate the relative bioavailability, pharmacokinetics, safety and tolerability of two candidate tablet formulations of ABT-072 when compared to that of the original capsule formulation suspended in liquid as a reference.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-072 | See arm description for more information |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2009-08-01
- First posted
- 2009-07-28
- Last updated
- 2010-10-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00947440. Inclusion in this directory is not an endorsement.